Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at $130.74 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $35.98 and a 12-month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The company has a market capitalization of $12,860.00, a PE ratio of -24.90 and a beta of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter last year, the business earned ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue was up 24.8% on a year-over-year basis. analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Fayerweather Charles acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $230,000. Watch Point Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $235,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $235,000. Security National Bank of SO Dak acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $247,000. Finally, Boston Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $247,000. Hedge funds and other institutional investors own 88.39% of the company’s stock.

ALNY has been the subject of a number of research analyst reports. Jefferies Group raised their target price on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. Chardan Capital reiterated a “buy” rating and set a $124.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, September 20th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $146.00 price objective (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Finally, Sanford C. Bernstein reiterated a “buy” rating and set a $135.00 price objective (up previously from $94.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $121.20.

TRADEMARK VIOLATION NOTICE: “Michael Mason Sells 36,745 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/michael-mason-sells-36745-shares-of-alnylam-pharmaceuticals-inc-alny-stock/1800723.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.